Since SET8 has been implicated in the developmentof a variety of cancers and the widespread use of cisplatin as a chemotherapeutic agent formost solid tumors, but with known nephrotoxicity, the results from this study suggest thatcombined administration of SET8 inhibitors with cisplatin could enhance tumor eradicationwhile simultaneously protecting against AKI. Here, KMT5A is linked to cancer.